Revision of the American Joint Committee on cancer staging system for breast cancer

Journal of Clinical Oncology

Volumn 20, Issue 17, 2002, Pages 3628-3636

  Singletary, S Eva ^a   Allred, Craig ^a   Ashley, Pandora ^a   Bassett, Lawrence W ^a   Berry, Donald ^a   Bland, Kirby I ^a   Borgen, Patrick I ^a   Clark, Gary ^a   Edge, Stephen B ^a   Hayes, Daniel F ^a   Hughes, Lorie L ^a   Hutter, Robert V P ^a   Morrow, Monica ^a   Page, David L ^a   Recht, Abram ^a   Theriault, Richard L ^a   Thor, Ann ^a   Weaver, Donald L ^a   Wieand, H Samuel ^a   Greene, Frederick L ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; CANCER CELL; CANCER REGISTRY; CANCER SIZE; CANCER STAGING; CERVICAL LYMPH NODE; CLINICAL PRACTICE; CLINICAL PROTOCOL; EVIDENCE BASED MEDICINE; HUMAN; LYMPH NODE METASTASIS; MEDICAL SOCIETY; MEDICAL TECHNOLOGY; METASTASIS; PRACTICE GUIDELINE; PRIORITY JOURNAL;

BREAST NEOPLASMS; FEMALE; HUMANS; LYMPHATIC METASTASIS; NEOPLASM STAGING; PRACTICE GUIDELINES; SENTINEL LYMPH NODE BIOPSY;

EID: 0036731788     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2002.02.026     Document Type: Article

References (48)

1. American Joint Committee on Cancer Prognostic Factors Consensus Conference
2. Prognostic factors in breast cancer: College of American Pathologists Consensus Statement 1999
3. Micrometastases to axillary lymph nodes from carcinoma of breast: Detection by immunohistochemistry and prognostic significance
4. Detection and significance of occult metastases in node-negative breast cancer
5. Prognostic significance of occult lymph node metastases in node-negative breast cancer
6. Prognostic significance of cytokeratin-positive breast cancer metastases
7. Occult metastases in the axillary lymph nodes of patients with breast cancer node-negative by clinical and histologic examination and conventional histology
8. Prognostic significance of breast cancer axillary lymph node micrometastases assessed by two special techniques: Re-evaluation with longer follow-up
9. RT-PCR increases detection of breast cancer sentinel lymph node micrometastases
10. Looking forward in diagnostic pathology: The molecular superhighway
11. Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases
12. erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer
13. Outcome of extensive evaluation before adjuvant therapy in women with breast cancer and 10 or more positive axillary lymph nodes
14. Radiation therapy and survival in breast cancer patients with 10 or more positive axillary lymph nodes treated with mastectomy
15. Dose-dense adjuvant chemotherapy with epirubicin monotherapy in patients with operable breast cancer and ≥ 10 positive axillary lymph nodes: A feasibility study
16. Management and survival of female breast cancer: Results of a national survey by the American College of Surgeons
17. Adverse prognostic significance of infraclavicular lymph nodes detected by ultrasonography in patients with locally advanced breast cancer
18. The dissection of internal mammary nodes does not improve the survival of breast cancer patients: 30-year results of a randomized trial
19. Comprehensive review of the management of internal mammary lymph node metastases in breast cancer
20. The results of radical operations for the cure of cancer of the breast
21. The significance of a supraclavicular node metastasis in patients with breast cancer: A literature review
22. Long-term results of combined-modality therapy for locally advanced breast cancer with ipsilateral supraclavicular metastases: The University of Texas M.D. Anderson Cancer Center Experience
23. Systemic treatment following sentinel lymph node biopsy in breast cancer: Who, what, and why?
24. Sentinel lymph node biopsy is accurate after neoadjuvant chemotherapy for breast cancer
25. Gamma probe sentinel node localization and biopsy in breast cancer patients treated with a neoadjuvant chemotherapy scheme
26. Sentinel lymph node biopsy after neoadjuvant chemotherapy for breast cancer
27. Is sentinel lymph node biopsy reliable and indicated after preoperative chemotherapy in patients with breast carcinoma?
28. Sentinel node biopsy following neoadjuvant chemotherapy in breast cancer: Results from NSABP B-27
29. Increased false negative sentinel node biopsy rates after preoperative chemotherapy for invasive breast carcinoma
30. Sentinel lymphadenectomy after neoadjuvant chemotherapy for breast cancer may reliably represents the axilla except for inflammatory breast cancer
31. Preoperative chemotherapy and sentinel lymphadenectomy for breast cancer
32. γber assymetrische zelltheilung in epithelkrebsen und deren biologische bedeutung
33. Varying degrees of malignancy in cancer of the breast
34. Pathological prognostic factors in breast cancer: I. The value of histologic grade in breast cancer - Experience from a large study with long-term follow-up
35. Histologic grading of breast carcinoma: A reproducibility study
36. Interobserver reproducibility of the Nottingham modification of the Bloom and Richardson histologic grading scheme for infiltrating ductal carcinoma
37. Histologic grading of breast carcinomas: A study of interobserver agreement
38. Pathological prognostic factors in stage I (T1N0M0) and stage II (T1N1M0) breast carcinoma: A study of 644 patients with median follow-up of 18 years
39. Relationship among outcome, stage of disease, and histologic grade for 22, 616 cases of breast cancer
40. Should all patients with node-negative breast cancer receive adjuvant therapy?
41. Comparison of the prognostic value of Scarff-Bloom-Richardson and Nottingham histologic grades in a series of 825 cases of breast cancer: Major importance of the mitotic count as a component of both grading systems
42. The prognosis of small primary breast cancers
43. Predictors of recurrence for patients with small (one centimeter or less) localized breast cancer (T1a,bN0M0)
44. The prognostic value of p53 and c-erb B-2 immunostaining is overrated for patients with lymph node negative breast cancer
45. Omission of histologic grading from clinical decision making may result in overuse of adjuvant therapies in breast cancer: Results from a nationwide study
46. Prognostic factors in node-negative breast cancer: A review of studies with sample size more than 200 and follow-up more than 5 years